MedTrace Logo

PAC-14028 in Healthy Male Volunteers

NCT01264224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-01-22

No results posted yet for this study

Summary

1. Primary Objective:

* To evaluate safety and tolerability of single and multiple oral dosing of PAC-14028 in healthy male volunteers.
2. Secondary Objective:

* To evaluate pharmacokinetics and pharmacodynamics of single and multiple oral dosing of PAC-14028 in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

PAC-14028

tablets, oral administration, single/multiple dosing, dose escalation

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, M.D., Ph.D. · Seoul National University Hospital, Clinical Trials Center/Clinical Research Institute

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01264224 on ClinicalTrials.gov